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Active Bacterial Core Surveillance (ABCs) Report 
Emerging Infections Program Network 
Methicillin-Resistant Staphylococcus aureus, 2011
ABCs Areas 
California (3 county San Francisco Bay area); Colorado (5 county Denver area); Connecticut; Georgia (8 county Atlanta area); Maryland (Baltimore 
City and County); Minnesota (2 metro Twin City counties); New York (1 Rochester county); Oregon (3 county Portland area); Tennessee (1 Nashville 
county).   
 
ABCs Population 
The surveillance areas represent 19,393,677 persons 
Source: National Center for Health Statistics bridged-race vintage 2011 postcensal file.   
 
ABCs Case Definition 
Invasive methicillin-resistant Staphylococcus aureus (MRSA) disease:  isolation of MRSA from a normally sterile site in a resident of the surveillance 
area in 2011.  Cases of disease are classified into one of three epidemiologic classifications.  A case is classified as hospital-onset (HO) if the MRSA 
culture was obtained on or after the fourth calendar day of hospitalization, where admission is hospital day 1;  as healthcare-associated 
community-onset (HACO) if the culture was obtained in an outpatient setting  or before the fourth calendar day of hospitalization and had one of 
more of the following: 1) a history of hospitalization, surgery, dialysis, or residence in a long term care facility in the previous year, or 2) the 
presence of a central vascular catheter (CVC) within 2 days prior to MRSA culture; and as community-associated (CA) if none of the previously 
mentioned criteria are met. 
 
ABCs Methodology 
ABCs personnel routinely contacted all microbiology laboratories serving acute care hospitals in their area to identify cases. Standardized case 
report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified 
case.  Convenience samples of isolates were collected and sent to CDC for routine testing, including: antimicrobial susceptibility testing, toxin 
testing and SCCmec typing. Pulsed field gel electrophoresis (PFGE) of all isolates was discontinued in 2008; an inferred PFGE algorithm was 
developed based on microbiologic and molecular characteristics of isolates.  The algorithm has been validated for use with isolates collected 
though this surveillance only (http://www.cdc.gov/HAI/settings/lab/inferred-PFGE-algorithm.html).  Regular laboratory audits were performed to 
ensure completeness of case detection. 
 
Rates of invasive MRSA disease among all patients were calculated using population estimates for 2011.  Cases with unknown race were assigned 
race based on distribution of known race and gender by EIP site.  Confidence intervals for nationally estimated incidence rates of disease and 
mortality were calculated based on the gamma distribution (Stat Med, 1997 16:791-801).   
 
Rates of invasive MRSA disease among patients who were undergoing chronic dialysis treatment were calculated using the December 31, 2010 
point prevalent counts of patients on dialysis from the United States Renal Data System (USRDS) (http://www.usrds.org/adr.htm).    
 
ABCs Results 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Distribution of cases, deaths and PFGE  type by Epidemiological Classification 
MRSA 
Class 
No. (Rate)  
Cases b 
No. (Rate)  
Deaths c 
Inferred PFGE Type (n,%)d 
Tot N USA100 USA300 
USA500/ 
Iberian 
CA 1010 (5.2) 100 (0.5) 306 81 (26.5) 192 (62.8) 9 (2.9) 
HCA a 3780 (19.5) 532 (2.7) 986 478 (48.5) 312 (31.6) 88 (8.9) 
HO 868 (4.5) 182 (0.9) 220 122 (55.5) 56 (25.5) 17 (7.7) 
HACO 2912 (15.0) 350 (1.8) 766 356 (46.5) 256 (33.4) 71 (9.3) 
a
 HCA: Healthcare-associated invasive MRSA infection; sum of patients that are classified 
as  either the HO or HACO classes 
b 
n= 82 epidemiologic category unknown 
c
 n=18;  epidemiologic category unknown 
d
 isolates were eligible for testing at CDC 
Reported Race among 4872 Cases 
Race                               No.    (Rate) a          
White  2743 (20.1) 
Black  1542   (41.5) 
Other  126 (6.2) 
 
Unknown race (n=461) distributed amongst known 
a 
Cases per 100,000 population for ABCs areas (crude rates) 
Reported Cases on Chronic Dialysis (n=960) 
Dialysis and Access Type No.   (%) 
Type of dialysis   
      Peritoneal  30 (3.1) 
      Hemodialysis  929 (96.9) 
AV Fistula/Graft 348 (37.5) 
CVC 511 (55.0) 
Unknown 70 (7.5) 
      Unknown  1 
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Reported Clinical Syndrome by Epidemiological Class 
Syndrome a 
CA 
(n=1010) 
HACO 
(n=2912) 
HO 
(n=868) 
 No. (%) No. (%) No. (%) 
Bloodstream Infection b    
with other syndrome 528 (52.3) 1503 (51.6) 313 (36.1) 
with no other syndrome 246 (24.4) 949 (32.6) 306 (35.3) 
Pneumonia 161 (15.9) 441 (15.1) 146 (16.8) 
Lower Respiratory Infection c 52 (5.2) 127 (4.4) 58 (6.7) 
Osteomyelitis 130 (12.9) 316 (10.9) 113 (13.0) 
Endocarditis 74 (7.3) 150 (5.2) 48 (5.5) 
Cellulitis 189 (18.7) 222 (7.6) 71 (8.2) 
Wounds     
Surgical d 15 (1.5) 185 (6.4) 34 (3.9) 
Decubitus/Pressure Ulcers 16 (1.6) 84 (2.9) 21 (2.4) 
Other Wounds/Skin Abscesses e 7 (0.5) 23 (0.8) 6 (0.7) 
Traumatic 13 (1.3) 16 (0.6) 8 (0.9) 
a 
Some case patients had more than one syndrome. 
b 
Sepsis or catheter site infection or AV fistula infection only are included in BSI with other syndrome. 
c 
Lower Respiratory Infection is defined as:  a patient with pneumonia documented in their discharge 
summary, who has a positive MRSA non-sterile respiratory specimen with accompanying chest radiology 
results documenting any of the following: bronchopneumonia/pneumonia, air space density/opacity, new 
or changed infiltrates. 
d
 Combines deep tissue/organ infection and infection of a surgical wound, post operatively. 
e 
Category includes skin abscess, necrotizing fasciitis, gangrene, non-traumatic wounds. 
 
National Estimates and Adjusted Incidence Rates of Invasive MRSA Infections 
Epidemiologic 
Category 
Estimated Cases of Infection 
Non-Dialysis Patients Dialysis Patients Total 
 Estimated 
No. 
Incidence Rate  
(Confidence Interval) a 
Estimated 
No. 
Incidence Rate  
(Confidence Interval) b 
Estimated 
No. 
Incidence Rate 
(Confidence Interval) 
CA 16,560 5.32 (4.11-7.00) NA NA 16,560 5.31 (4.11-7.00) 
HCA 47,340 15.21 (13.27-17.62) 15,169 3654.19 (2820.46-4739.00) 62,509 20.06 (17.01-23.91) 
      HO 12,464 4.01 (3.02-5.44) 1,692 407.71  (174.70-850.84) 14,156 4.54 (3.24-6.56) 
      HACO 34,876 11.21 (9.62-13.18) 13,477 3247.45 (2472.51-4246.00) 48,353 15.52 (12.90-18.82) 
Overall c 65,296 20.98 (18.58-23.86) 15,169 3654.19 (2820.46-4739.00) 80,461 25.82 (22.31-30.14) 
a
 National Estimates and Incidence (no. per 100,000 population per year) are adjusted for age,  race, gender and receipt of chronic dialysis using 2011 US 
Census Data.  
b National Estimates and Incidence (no. per 100,000 dialysis patients per year) for dialysis patients are adjusted for age, race and gender using 2010 USRDS 
point prevalence data.   
c 
82 cases could not be classified into an epidemiological category or category is unknown and therefore are counted in the overall estimate only.   
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National Metric for Healthy People 2020 and the Department of Health and Human Services Action Plan to Prevent Healthcare-Associated 
Infections 
 
 
 
 
 
 
 
ABCs Discussion 
Surveillance data from 2011 represent the seventh full year of performing population-based surveillance for invasive MRSA infections through the 
Emerging Infections Program/Active Bacterial Core Surveillance Activity.  
 
Overall, compared to the baseline incidence (2007-2008 calendar years) identified in the HHS Action Plan, there was a decrease of 25.92%.  
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National Estimates and Adjusted Incidence Rates for Mortality among Cases 
Epidemiologic Class Estimated No. Mortality Rate 
(Confidence Interval) a 
CA 1,764 0.57 (0.30-1.04) 
HCA 9,197 2.95 (2.02-4.54) 
HO 3,126 1.00 (0.51-2.06) 
HACO 6,071 1.95 (1.26-3.12) 
Overall b 11,285 3.62 (2.58-5.31) 
a National Estimates and Mortality Rate (no. per 100,000 population per year) 
are adjusted for age, race, gender and receipt of chronic dialysis using 2011 US 
Census Data 
b 82  cases could not be classified into an epidemiological category or category is 
unknown and therefore are counted in the overall estimate only. 
 Disease Rate  Estimate of Cases in United States. a 
Baseline (07-08) 2011 % Change Baseline (07-08) 2011 Difference 
HCA  27.08 20.06 -25.92 82,000 62,500 19,500 
a
  Disease Rate (no. per 100,000 population per year) and National Estimates are adjusted for age, race, 
gender and receipt of chronic dialysis  using 2011 US Census Data
 
 
